TWI912393B - 適用於新生兒的組成物 - Google Patents

適用於新生兒的組成物

Info

Publication number
TWI912393B
TWI912393B TW110138769A TW110138769A TWI912393B TW I912393 B TWI912393 B TW I912393B TW 110138769 A TW110138769 A TW 110138769A TW 110138769 A TW110138769 A TW 110138769A TW I912393 B TWI912393 B TW I912393B
Authority
TW
Taiwan
Prior art keywords
composition
igf
months
polysorbate
weeks
Prior art date
Application number
TW110138769A
Other languages
English (en)
Chinese (zh)
Other versions
TW202233228A (zh
Inventor
米勒 納孜拉 薩拉馬特
凱薩琳 泰勒
冰 何
塔洽雅 印卓尼爾 柏哈塔
琳達 韓
班尼塔 阿姆斯丹
詹姆士 克蘭茲
Original Assignee
英商奧克希爾生物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商奧克希爾生物有限公司 filed Critical 英商奧克希爾生物有限公司
Publication of TW202233228A publication Critical patent/TW202233228A/zh
Application granted granted Critical
Publication of TWI912393B publication Critical patent/TWI912393B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110138769A 2020-10-19 2021-10-19 適用於新生兒的組成物 TWI912393B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063093696P 2020-10-19 2020-10-19
US63/093,696 2020-10-19

Publications (2)

Publication Number Publication Date
TW202233228A TW202233228A (zh) 2022-09-01
TWI912393B true TWI912393B (zh) 2026-01-21

Family

ID=78622033

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110138769A TWI912393B (zh) 2020-10-19 2021-10-19 適用於新生兒的組成物

Country Status (24)

Country Link
US (1) US20230381285A1 (cg-RX-API-DMAC7.html)
EP (2) EP4228676B1 (cg-RX-API-DMAC7.html)
JP (2) JP7827315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230113287A (cg-RX-API-DMAC7.html)
CN (1) CN117098547A (cg-RX-API-DMAC7.html)
AU (1) AU2021364523A1 (cg-RX-API-DMAC7.html)
CA (1) CA3194764A1 (cg-RX-API-DMAC7.html)
DK (1) DK4228676T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005966T3 (cg-RX-API-DMAC7.html)
FI (1) FI4228676T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250193T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070409T2 (cg-RX-API-DMAC7.html)
IL (1) IL301688A (cg-RX-API-DMAC7.html)
LT (1) LT4228676T (cg-RX-API-DMAC7.html)
MX (1) MX2023004426A (cg-RX-API-DMAC7.html)
PL (1) PL4228676T3 (cg-RX-API-DMAC7.html)
PT (1) PT4228676T (cg-RX-API-DMAC7.html)
RS (1) RS66493B1 (cg-RX-API-DMAC7.html)
SA (1) SA523440271B1 (cg-RX-API-DMAC7.html)
SI (1) SI4228676T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500093T1 (cg-RX-API-DMAC7.html)
TW (1) TWI912393B (cg-RX-API-DMAC7.html)
WO (1) WO2022086953A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202303162B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250099541A1 (en) 2022-01-19 2025-03-27 Oak Hill Bio Ltd Compositions and methods for reducing oxidation of igf-1/igfbp
CA3248280A1 (en) 2022-05-04 2023-11-09 Oak Hill Bio Limited POLYTHERAPY FOR PREMATURE INFANTS
WO2023242439A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
EP4598630A1 (en) * 2022-10-04 2025-08-13 Oak Hill Bio Limited Method of treating neonates with igf-1 complex

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190151411A1 (en) * 2017-09-11 2019-05-23 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
JP2008543839A (ja) * 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
RU2558821C2 (ru) * 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CA2897062A1 (en) * 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Lyophilization process
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
US20250099541A1 (en) * 2022-01-19 2025-03-27 Oak Hill Bio Ltd Compositions and methods for reducing oxidation of igf-1/igfbp
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190151411A1 (en) * 2017-09-11 2019-05-23 Shire Human Genetic Therapies, Inc. Methods and compositions for treating chronic lung diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 David Ley ET AL: rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial The Journal of Pediatrics vol. 206 2019-03-01 1-34 *

Also Published As

Publication number Publication date
PT4228676T (pt) 2025-01-24
JP2026102579A (ja) 2026-06-23
SMT202500093T1 (it) 2025-03-12
IL301688A (en) 2023-05-01
WO2022086953A9 (en) 2022-07-07
AU2021364523A1 (en) 2023-04-06
JP2023550203A (ja) 2023-11-30
ES3005966T3 (en) 2025-03-17
MX2023004426A (es) 2023-08-04
LT4228676T (lt) 2025-02-10
CN117098547A (zh) 2023-11-21
HUE070409T2 (hu) 2025-06-28
HRP20250193T1 (hr) 2025-04-11
SA523440271B1 (ar) 2025-04-10
EP4534073A2 (en) 2025-04-09
EP4228676A1 (en) 2023-08-23
US20230381285A1 (en) 2023-11-30
SI4228676T1 (sl) 2025-03-31
WO2022086953A1 (en) 2022-04-28
KR20230113287A (ko) 2023-07-28
FI4228676T3 (fi) 2025-02-26
CA3194764A1 (en) 2022-04-28
EP4534073A3 (en) 2025-05-14
RS66493B1 (sr) 2025-03-31
DK4228676T3 (da) 2025-01-20
PL4228676T3 (pl) 2025-04-07
EP4228676B1 (en) 2025-01-08
JP7827315B2 (ja) 2026-03-10
ZA202303162B (en) 2024-08-28
TW202233228A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
JP7827315B2 (ja) 新生児における使用に好適な組成物
AU2024227601B2 (en) Methods and compositions for treating chronic lung diseases
US20150216943A1 (en) Method and product for treatment and/or prevention of complications of prematurity
JP2009132682A (ja) Igf−iの投与法
EA049095B1 (ru) Композиции, подходящие для применения у новорожденных
HK40099225B (en) Compositions suitable for use in neonates
HK40099225A (en) Compositions suitable for use in neonates
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
HK40033881A (en) Methods and compositions for treating chronic lung diseases
AU2024373079A1 (en) Methods for treating premature newborn infants by administration of recombinant human surfactant protein d (rhsp-d)
US20060122102A1 (en) Methods and preparations for curing critically ill patients